India
Every company in the roster headquartered in India.
Every company in the roster headquartered in India.
8 of 8 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Dr. Reddy's LaboratoriesRDY · NYSE | 4 assets: 2 approved, 2 Ph 3 | PyrotinibPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Pyrotinib · Phase 1/2 | $12.5B | $172MMar 2025 | Cash-flow positive | $323M |
Alkem LaboratoriesALKEM · NSE | 1 asset: 1 Ph 3 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
BioconBIOCON · NSE | 3 assets: 2 approved, 1 Ph 1 | ItolizumabPhase 1 · Psoriasis | None on record | — | $259MMar 2026 | — | $111M |
CiplaCIPLA · NSE | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | VildagliptinPhase 3 · Type 2 DiabetesPartial signal | Mar 2027Afrezza · Phase 2 | — | — | — | — |
Sun Pharmaceutical IndustriesSUNPHARMA · NSE | 6 assets: 4 approved, 1 Ph 3, 1 Ph 2 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | Apr 2027Utreglutide · Phase 2 | — | $1.0BMar 2026 | Profitable | $401M |
Suven Life SciencesSUVEN · NSE | 2 assets: 1 Ph 3, 1 Ph 2 | MasupirdinePhase 3 · Alzheimer's DiseasePartial signal | Dec 2026Masupirdine · Phase 3 | — | — | — | $33M |
Biocon BiologicsPrivate | 3 assets: 2 approved, 1 Ph 1 | Bmab1700Phase 1 | 16 Aug 2027Bmab1700 · Phase 1 | — | — | — | — |
Intas PharmaceuticalsPrivate | 3 assets: 2 Ph 3, 1 other | HD204Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.